Nabla Bio
New accelerator entry · 2021-08-27 · the record
In their words
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
What the record says
- One of 59 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Nabla Bio
- Source Check — verify what Nabla Bio states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Nabla Bio for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Nabla BioYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Nabla Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.